Therefore, the NF-κB signalling pathway presents itself as a possible therapeutic target for the treatment of TSC, and combinatory approaches with traditional mTORC1 inhibitors may prove more effective as an adjunct therapy. Here, NFKB1 is linked to tuberous sclerosis.